Reintroduction of Proposal for Campaign Against Viral Hepatitis in Nigeria

We wish to bring to your attention the reintroduction of a life-saving proposal that was initially submitted on the 10th of September, 2022. This proposal aims to initiate a comprehensive campaign against viral hepatitis in Nigeria, focusing on addressing the alarming prevalence of the disease and providing much-needed treatment to affected individuals.

As you may recall, the initial proposal highlighted the urgency of this campaign, given that viral hepatitis is more deadly and widespread than other diseases such as HIV/AIDS and malaria. Unfortunately, due to funding challenges, the project did not progress as intended. However, the need for this initiative remains critical, and the current landscape makes it even more imperative to take action.

The details of the proposal remain unchanged, emphasizing the provision of Direct Acting Antiviral (DAA) medications to 50,000 Nigerians infected with Hepatitis C. The project still represents an essential Corporate Social Responsibility (CSR) opportunity for the Joint Venture Partners (JVPs) of NNPC Ltd.

Given the ongoing health challenges in Nigeria, including the exacerbating effects of COVID-19 on individuals with compromised immunity, it is crucial to revisit this proposal and take swift action. The benefits of implementing this project will not only save lives but also significantly enhance the health sector's impact under the current administration.

We kindly request that this proposal be reconsidered for adoption and implementation, as the conditions necessitating it have only intensified.

Thank you for your attention and consideration. We look forward to the possibility of collaborating to achieve these critical health outcomes.